Google Search
Search
Already a Member ?
Investment Opportunities In Apis-ksms-drug Intermediates Bulk Drug Industries. | |
| Investment Opportunities in APIs-KSMs-Drug Intermediates Bulk Drug Industries. Cabinet Approves Promotion of Domestic Manufacturing of Critical Key Starting Materials-Drug Intermediates and Active Pharmaceutical Ingredients in the Country. Key Starting Materials (KSMs)/Drug Intermediates KSMs from the essential medicines list for strategic reasons posed by the COVID-19. Role of Government towards (KSMs)/Drug Intermediates The Union Cabinet chaired by the Prime Minister, Shri Narendra Modi has approved the following schemes: The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6, 940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. • Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Impact: Promotion of Bulk Drug Parks: The scheme is expected to reduce manufacturing cost of bulk drugs in the country and dependency on other countries for bulk drugs. Production Linked Incentive Scheme: • The scheme intends to boost domestic manufacturing of critical KSMs/Drug Intermediates and APIs by attracting large investments in the sector to ensure their sustainable domestic supply and thereby reduce India's import dependence on other countries for critical KSMs/Drug Intermediates and APIs. • It will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over 8 years. Implementation: Promotion of Bulk Drug Parks The scheme will be implemented by State Implementing Agencies (SIA) to be set up by the respective State Governments and the target is to set up 3 mega Bulk Drug Parks. Production Linked Incentive Scheme The scheme will be implemented through a Project Management Agency (PMA) to be nominated by the Department of Pharmaceuticals. The Scheme will be applicable only for manufacturing of 53 identified critical bulk drugs (KSMs/Drug Intermediates and APIs). Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Benefits: • Common infrastructure facilities would be created with the financial assistance under the sub-scheme in 03 Bulk Drug Parks. • It is expected to reduce manufacturing cost and dependency on other countries of Bulk Drug in the country. Related videos: - Manufacturing Business Ideas in Pharmaceutical Industry Manufacturing of Pharmaceutical Bulk Drugs and Medicine Pharmaceutical Pellets and Granules Pharmaceutical Manufacturing Unit Indian Pharma Industry: An Investment Opportunity Manufacturing Business Ideas in Pharmaceutical Industry List of Critical KSMs/Drug Intermediates and APIs Fermentation Based 04 KSMs/Drug Intermediates and Corresponding APIs 1. Penicillin G/6-Amino Penicillinc Acid (6-APA) 2. Cephalosporin C/7-Amino Cephalosporanic Acid (7-ACA) 3. Erythromycin Thiocyanate/TIOC 4. Potassium Clavulanate Fermentation Based 10 Niche KSMs/Drug Intermediates and Corresponding APIs 1. Cyclins (Tetracycline, Oxycycline, Doxyxcline) 2. Aminoglycosides (Gentamycin) 3. Aminoglycosides (Neomycin) 4. Aminoglycosides (Streptomycin) 5. Steroids (Betamethasone) 6. Steroids (Dexamethasone) 7. Steroids (Prednisolone) 8. Anti TB (Rifampicin) 9. Vitamins and Nutraceuticals (Vitamin B6) 10. Vitamins and Nutraceuticals (Vitamin B1) Chemical Synthesis Based 04 KSMs/Drug Intermediates and Corresponding APIs (with backward integration) 1. Dicyandiamide (DCDA) 2. Para-aminophenol 3. 2-Methyl -5 Nitro- Imidazole (2-MNI) including Imidazoles. 4. 1, 1 Cyclohexane Diacetic Acid (CDA) Other Chemical Synthesis Based 23 KSMs/Drug Intermediates and Corresponding APIs (with backward integration) 1) Levofloxacin 2) Sulfadiazine 3) Ciprofloxacin 4) Ofloxacin 5) Norfloxacin 6) Artesunate 7) Telmisartan 8) Losartan 9) Valsartan 10) Olmesartan 11) Atorvastatin 12) Acyclovir 13) Lopinavir 14) Ritonavir 15) Oxcarbazepine 16) Carbamazepine 17) Levodopa 18) Carbidopa 19) Levetiracetam 20) Aspirin 21) Diclofenac Sodium 22) Tinidazole 23) Ornidazole Market The Indian pharmaceutical industry is the 3rd largest in the world by volume. However, despite this achievement, India is significantly dependent on the import of basic raw materials, viz., Bulk Drugs that are used to produce medicines. In some specific bulk drugs the import dependence is 80 to 100%. The government has plans to put in place a production-linked incentive (PLI) scheme to boost domestic manufacturing of critical key starting materials (KSMs) or drug intermediates, used to make bulk drugs, as well as APIs. That PLI could cost $911.5 million over the next eight years. India imports 53 APIs and KSMs from China. According to the Trade Promotion Council of India (TCPI), India imports 70% of its API requirements from China, mostly antibiotics and vitamins. In 2018-19, Indian pharma companies imported bulk drugs and intermediates worth $2.4 billion from China. The Indian pharmaceutical market should grow from nearly $34.3 billion in 2020 to more than $45 billion by 2025 million. Quantum of Incentive The fermentation based eligible, incentive for first four years (2022-2023 to 2025-2026) would be 20%, for fifth year (2026-27) incentive would be 15% and the sixth year (2027-2028) incentive would be 5%; on incremental sale of KSMs/Drug Intermediates/APIs. For chemically synthesis eligible products, incentive for five years (2021-2022 to 2025-2026) would be 10% on incremental sales of KSMs/Drug Intermediates/APIs. Tags:- #Levofloxacin #Sulfadiazine #Ciprofloxacin #Ofloxacin #Norfloxacin #Artesunate #Telmisartan #Losartan #Valsartan #Olmesartan #Atorvastatin #Acyclovir #Lopinavir #Ritonavir #Oxcarbazepine #Carbamazepine #Levodopa #Carbidopa #Levetiracetam #Aspirin #Diclofenac Sodium #Tinidazole #Ornidazole #businessopportunity #projectreport #DetailedProjectReport #businessconsultant #businessfeasibilityreport #BusinessPlan #startyourbusiness #investmentopportunity #growyourbusiness #startups #business #covidbusiness #covid19 #covidsmallbusiness #APIBusiness #ActivePharmaceuticalIngredient | |
| Plant capacity: - | Plant & machinery: - |
| Working capital: - | T.C.I: - |
| Return: 1.00% | Break even: N/A |
Email Us |
 Add to Inquiry Basket | |
We can provide you detailed project reports on the following topics. Please select the projects of your interests.
Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.
We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.
Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.
Information- One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
- One Crore is equivalent to ten million (10,000,000)
- T.C.I is Total Capital Investment
- We can modify the project capacity and project cost as per your requirement.
- We can also prepare project report on any subject as per your requirement.
- Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.
About NIIR PROJECT CONSULTANCY SERVICES | Hide  |
NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.
Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.
NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.
Copyright © 2003-2021 NPCS.
